{"id":762989,"date":"2023-06-12T08:21:44","date_gmt":"2023-06-12T12:21:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/"},"modified":"2023-06-12T08:21:44","modified_gmt":"2023-06-12T12:21:44","slug":"cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/","title":{"rendered":"Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease"},"content":{"rendered":"

<\/p>\n

Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae<\/sup> Cyclo\u2122 for Alzheimer\u2019s Disease<\/b><\/p>\n

GAINESVILLE, Fla.–(BUSINESS WIRE<\/a>)–Cyclo Therapeutics, Inc.<\/a> (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Communication from the European Patent Office (EPO) regarding Cyclo Therapeutics\u2019 European Patent Application No.19805439.7 titled, \u201cMethods for Treating Alzheimer\u2019s Disease<\/i>.\u201d The EPO Communication stated that \u201c[t]he newly filed claims are considered to be allowable\u201d and that \u201c[t]he applicant is therefore requested to bring the description into conformity with these claims.\u201d<\/p>\n

\nN. Scott Fine, CEO of Cyclo Therapeutics, commented, \u201cWe continue to execute our strategy designed to bolster our patent estate to protect Trappsol\u00ae<\/sup> Cyclo\u2122 for our lead indications in key markets worldwide. This European patent application is an important component of our strategy given the launch of our early onset Alzheimer\u2019s disease clinical development program this year.\u201d<\/p>\n

About Cyclo Therapeutics<\/i><\/b><\/p>\n

\nCyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease. The Company\u2019s Trappsol\u00ae<\/sup> Cyclo\u2122, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov<\/a>NCT02939547<\/a>, NCT02912793<\/a>, NCT03893071<\/a> and NCT04860960<\/a>). The Company is conducting a Phase 2b clinical trial using Trappsol\u00ae<\/sup> Cyclo\u2122 intravenously in early Alzheimer\u2019s disease (NCT05607615<\/a>) based on encouraging data from an Expanded Access program for Alzheimer\u2019s disease (NCT03624842<\/a>). Additional indications for the active ingredient in Trappsol\u00ae<\/sup> Cyclo\u2122 are in development. For additional information, visit the Company\u2019s website: www.cyclotherapeutics.com<\/a>.<\/p>\n

Safe Harbor Statement<\/i><\/b><\/p>\n

\nThis press release contains \u201cforward-looking statements\u201d about the company\u2019s current expectations about future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering. Statements that are not historical facts, such as \u201canticipates,\u201d \u201cbelieves\u201d and \u201cexpects\u201d or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company\u2019s future performance include the company\u2019s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company\u2019s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company\u2019s filings with the Securities and Exchange Commission, including, but not limited to, the company\u2019s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230612005123\/en\/<\/a><\/span><\/p>\n

\nJTC Team, LLC
\n
Jenene Thomas
\n
(833) 475-8247
\n
CYTH@jtcir.com<\/a><\/p>\n

KEYWORDS:<\/b> Europe United States North America Florida<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Other Science Clinical Trials Pharmaceutical Science Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Communication from the European Patent Office (EPO) regarding Cyclo Therapeutics\u2019 European Patent Application No.19805439.7 titled, \u201cMethods for Treating Alzheimer\u2019s Disease.\u201d The EPO Communication stated that \u201c[t]he newly filed claims are considered to be allowable\u201d and that \u201c[t]he applicant is therefore requested to bring the description into conformity with these claims.\u201d N. Scott Fine, CEO of Cyclo Therapeutics, commented, \u201cWe continue to execute our strategy … <\/p>\n

Continue reading “Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-762989","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Communication from the European Patent Office (EPO) regarding Cyclo Therapeutics\u2019 European Patent Application No.19805439.7 titled, \u201cMethods for Treating Alzheimer\u2019s Disease.\u201d The EPO Communication stated that \u201c[t]he newly filed claims are considered to be allowable\u201d and that \u201c[t]he applicant is therefore requested to bring the description into conformity with these claims.\u201d N. Scott Fine, CEO of Cyclo Therapeutics, commented, \u201cWe continue to execute our strategy … Continue reading "Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-12T12:21:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230612005123r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease\",\"datePublished\":\"2023-06-12T12:21:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\\\/\"},\"wordCount\":583,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230612005123r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\\\/\",\"name\":\"Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230612005123r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-06-12T12:21:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230612005123r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230612005123r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/","og_locale":"en_US","og_type":"article","og_title":"Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease - Market Newsdesk","og_description":"Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Communication from the European Patent Office (EPO) regarding Cyclo Therapeutics\u2019 European Patent Application No.19805439.7 titled, \u201cMethods for Treating Alzheimer\u2019s Disease.\u201d The EPO Communication stated that \u201c[t]he newly filed claims are considered to be allowable\u201d and that \u201c[t]he applicant is therefore requested to bring the description into conformity with these claims.\u201d N. Scott Fine, CEO of Cyclo Therapeutics, commented, \u201cWe continue to execute our strategy … Continue reading \"Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-12T12:21:44+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230612005123r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease","datePublished":"2023-06-12T12:21:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/"},"wordCount":583,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230612005123r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/","name":"Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230612005123r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-06-12T12:21:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230612005123r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230612005123r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-announces-allowance-of-patent-from-european-patent-office-for-trappsol-cyclo-for-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol\u00ae Cyclo\u2122 for Alzheimer\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/762989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=762989"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/762989\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=762989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=762989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=762989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}